The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

49 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
From carbohydrates to drug-like fragments: Rational development of novela-amylase inhibitors.EBI
Freie Universit£T Berlin
Synthesis and biological evaluation of 3,5-disubstituted-4-alkynylisoxozales as a novel class of HSP90 inhibitors.EBI
Chengdu University Of Tcm
Volume of Distribution in Drug Design.EBI
Pharmacokinetics
Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.EBI
Sloan-Kettering Institute For Cancer Research
Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.EBI
Tufts University
Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.EBI
Nerviano Medical Sciences
Towards the discovery of drug-like epigallocatechin gallate analogs as Hsp90 inhibitors.EBI
Montclair State University
Differences in conformational dynamics between Plasmodium falciparum and human Hsp90 orthologues enable the structure-based discovery of pathogen-selective inhibitors.EBI
University Of Geneva
Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.EBI
China Pharmaceutical University
Identification of novel HSP90a/ß isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.EBI
Vertex Pharmaceuticals
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).EBI
Exelixis
Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.EBI
Seoul National University
Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.EBI
Astrazeneca
Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization.EBI
Vernalis
Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90.EBI
Merck Serono
Discovery of novel aminoquinazolin-7-yl 6,7-dihydro-indol-4-ones as potent, selective inhibitors of heat shock protein 90.EBI
Serenex
Heat shock protein 90: inhibitors in clinical trials.EBI
Biogen Idec
Potent cytotoxic C-11 modified geldanamycin analogues.EBI
Kosan Biosciences
Discovery and development of heat shock protein 90 inhibitors.EBI
Memorial Sloan-Kettering Cancer Center
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.EBI
Infinity Pharmaceuticals
Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90.EBI
Universit£
A small molecule that preferentially binds the closed conformation of Hsp90.EBI
San Diego State University
Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.EBI
Sanofi-Aventis Research And Development
Lead identification ofß-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90.EBI
Trinity College
ATPases as drug targets: insights from heat shock proteins 70 and 90.EBI
Vernalis R&D
Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.EBI
Trinity College
Recent developments in fragment-based drug discovery.EBI
Astex Therapeutics
Synthesis of Hsp90 dimerization modulators.EBI
Memorial Sloan-Kettering Cancer Center
High-throughput screening for Hsp90 ATPase inhibitors.EBI
The University Of Kansas
4-Amino derivatives of the Hsp90 inhibitor CCT018159.EBI
Vernalis
Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.EBI
Memorial Sloan-Kettering Cancer Center
Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.EBI
Memorial Sloan-Kettering Cancer Center
Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.EBI
Conforma Therapeutics
Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures.EBI
Ribotargets
Synthesis of novel fluorescent probes for the molecular chaperone Hsp90.EBI
Memorial Sloan-Kettering Cancer Center
Impacts of some antibiotics on human serum paraoxonase 1 activity.BDB
Atatürk University
Pharmacological and genetic characterization of two selective serotonin transporter ligands: 2-[2-(dimethylaminomethylphenylthio)]-5-fluoromethylphenylamine (AFM) and 3-amino-4-[2-(dimethylaminomethyl-phenylthio)]benzonitrile (DASB).BDB
National Institutes Of Health
[3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors.BDB
Croissy-Sur-Seine Paris